Market Place
Sourcing Support
Arrowhead Pharma To Webcast Q2 Fiscal 2026 Results
20 Apr 2026 //
PHARMIWEB
Arrowhead to Participate in Upcoming March 2026 Events
24 Feb 2026 //
BUSINESSWIRE
Arrowhead Pharma Reveals Q1 2026 Financial Report
05 Feb 2026 //
BUSINESSWIRE
Arrowhead Pharma To Webcast Q1 Fiscal 2026 Results
20 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma To Join January 2026 Conferences
23 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma Issues Inducement Grants Under Nasdaq 5635(c)(4)
15 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma To Join December 2025 Conferences
01 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals To Webcast Fiscal 2025 Year-End Results
06 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma To Join November 2025 Conferences
04 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma Discloses Inducement Grants Per Nasdaq LR
28 Oct 2025 //
BUSINESSWIRE
Arrowhead Pharma Finalizes Collaboration Deal with Novartis
21 Oct 2025 //
BUSINESSWIRE
Arrowhead Pharma to Join September 2025 Conferences
27 Aug 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals` Fiscal 2025 Q3 Results Released
07 Aug 2025 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
24 Jul 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal Q3 2025 Results
21 Jul 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals in June 2025 Investor Conferences
29 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Q2 2025 Results
12 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Join May 2025 Investor Conferences
07 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Q2 Fiscal 2025 Results
30 Apr 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Names Daniel Apel CFO
15 Apr 2025 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
04 Apr 2025 //
BUSINESSWIRE
Arrowhead & Sarepta Close Global License Agreement
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharma to Webcast Fiscal 2025 First Quarter Results
22 Jan 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Starts Phase 1/2a of ARO-INHBE for Obesity
23 Dec 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
19 Dec 2024 //
BUSINESSWIRE
Arrowhead Seeks Clearance for ARO-ALK7 in Obesity Study
03 Dec 2024 //
BUSINESSWIRE
Arrowhead to Participate in Upcoming December 2024 Conferences
02 Dec 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
26 Nov 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
05 Nov 2024 //
BUSINESSWIRE
Arrowhead Pharma Reports Inducement Grants under NASDAQ LR 5635(c)(4)
14 Oct 2024 //
BUSINESSWIRE
Arrowhead Presents Phase 3 Data On Plozasiran For Familial Chylomicronemia
03 Sep 2024 //
BUSINESSWIRE
Arrowhead To Present Plozasiran Phase 3 Data At ESC 2024
21 Aug 2024 //
BUSINESSWIRE
After clearing out heart drug, Arrowhead maps out obesity development plans
15 Aug 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Announces $500M Financing With Sixth Street
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
29 Jul 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
24 Jul 2024 //
BUSINESSWIRE
Arrowhead Axes Heart Disease Drug, Focuses on Another
26 Jun 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals presents new RNAi-based obesity program data.
24 Jun 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
31 May 2024 //
BUSINESSWIRE
Arrowhead Presents Zodasiran Phase 2 Data In Mixed Hyperlipidemia
29 May 2024 //
BUSINESSWIRE
Arrowhead plots next steps for RNAi therapies after mid-stage win
29 May 2024 //
ENDPTS
Arrowhead`s cholesterol drug hits the mark again in ph. 2 trial
28 May 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
09 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
02 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
29 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
26 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
24 Apr 2024 //
BUSINESSWIRE
Arrowhead`s plozasiran could reach $700M-plus in sales: report
16 Apr 2024 //
FIERCE PHARMA
Arrowhead reports full Phase 2b data for lipid drug, but Ionis is a step ahead
08 Apr 2024 //
PRESS RELEASE
Arrowhead Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
04 Mar 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals jumps amid takeover speculation
28 Feb 2024 //
SEEKING ALPHA
Arrowhead Pharmaceuticals expands board, adds new director from April
22 Feb 2024 //
PRESS RELEASE
Arrowhead axes assets, but spares staff, to save $100M a year
07 Feb 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
06 Feb 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
22 Jan 2024 //
BUSINESSWIRE
Arrowhead Closes Underwritten Offering with Gross Proceeds of $450.0M
05 Jan 2024 //
BUSINESSWIRE
Arrowhead Announces Pricing of $450.0M Underwritten Offering of Common Stock
03 Jan 2024 //
BUSINESSWIRE
